{"nctId":"NCT00258011","briefTitle":"Study of AldurazymeÂ® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease","startDateStruct":{"date":"2005-12"},"conditions":["Mucopolysaccharidosis I","Hurler Syndrome","Hurler-Scheie Syndrome","Scheie Syndrome"],"count":3,"armGroups":[{"label":"Aldurazyme (laronidase) treatment","type":"EXPERIMENTAL","interventionNames":["Biological: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)"]}],"interventions":[{"name":"Aldurazyme (Recombinant Human Alpha-L-Iduronidase)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent/assent of the patient or written informed consent of the parent(s) or the legal guardian(s), depending on the age of the patient, is required prior to any protocol-related procedures being performed; this includes information regarding hematopoietic stem cell transplantation (HSCT) in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative treatment for patients eligible for the trial and who have severe manifestations of MPS I with neurodegeneration.\n* Have a clinical diagnosis of MPS, confirmed by measurable clinical signs and symptoms of MPS I.\n* Have confirmed iduronidase deficiency with a leukocyte alpha-L-iduronidase enzyme activity level of less than 10.0% of the lower limit of the normal range of the measuring laboratory (SRL)\n\nExclusion Criteria:\n\n* The patient is under consideration for or has previously undergone hematopoietic stem cell transplantation.\n* The patient has acute hydrocephalus at the time of enrollment.\n* The patient has a clinically significant organic disease (with the exception of symptoms relating to MPS I) including: cardiovascular, hepatic, pulmonary, neurologic, or renal disease, other serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial or potentially decrease survival.\n* The patient has received any investigational product within 30 days prior to trial enrollment (exception: JC0498).\n* The patient has known severe hypersensitivity to JC0498 or components of the delivery solution.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety Evaluation","description":"Overall Safety Summary of Adverse Events (AEs) during Treatment Safety assessment was based on the incidence of AE reports.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Urinary Glycosaminoglycan (GAG) Excretion","description":"Percentage change in the concentration of GAG relative to creatinine in urine (ug GAG/mg creatinine) from baseline to last study visit. Greater decrease indicates greater response.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-68.0","spread":"12.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.9","spread":"7.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.6","spread":"11.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.0","spread":"9.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.6","spread":"12.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.5","spread":"5.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-75.2","spread":"10.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.7","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.9","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.9","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.1","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.7","spread":"20.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":3},"commonTop":["Nasopharyngitis","Otitis media","Oxygen saturation decreased","Heat rash","Conjunctivitis"]}}}